Patents by Inventor János Éles

János Éles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11026946
    Abstract: The present invention relates to new pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof that serve as GABAB receptor positive allosteric modulators. The invention al so relates to the process for producing such compounds. The invention further relates to pharmaceutical compositions comprising such compounds optionally in combination with two or more different therapeutic agents and the use of such compounds in methods for treating diseases and conditions mediated and modulated by the GABAB receptor positive allosteric mechanism. The invention al so provides a method for manufacture of medicaments useful in the treatment of such disorders.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: June 8, 2021
    Assignee: RICHTER GEDEON NYRT.
    Inventors: István Borza, Viktor Román, János Éles, Zsuzsa Hadady
  • Patent number: 10960007
    Abstract: The present invention relates to new pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof that serve as GABAB receptor positive allosteric modulators. The invention also relates to the process for producing such compounds. The invention further relates to pharmaceutical compositions comprising such compounds optionally in combination with two or more different therapeutic agents and the use of such compounds in methods for treating diseases and conditions mediated and modulated by the GABAB receptor positive allosteric mechanism. The invention also provides a method for manufacture of medicaments useful in the treatment of such disorders.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 30, 2021
    Assignee: RICHTER GEDEON NYRT.
    Inventors: István Borza, Viktor Román, János Éles, Zsuzsa Hadady, József Huszár
  • Publication number: 20200129515
    Abstract: The present invention relates to new pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof that serve as GABAB receptor positive allosteric modulators. The invention al so relates to the process for producing such compounds. The invention further relates to pharmaceutical compositions comprising such compounds optionally in combination with two or more different therapeutic agents and the use of such compounds in methods for treating diseases and conditions mediated and modulated by the GABAB receptor positive allosteric mechanism. The invention al so provides a method for manufacture of medicaments useful in the treatment of such disorders.
    Type: Application
    Filed: March 12, 2018
    Publication date: April 30, 2020
    Inventors: István BORZA, Viktor ROMÁN, János ÉLES, Zsuzsa HADADY
  • Publication number: 20200061068
    Abstract: The present invention relates to new pyrazolo[1,5-a]pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof that serve as GABAB receptor positive allosteric modulators. The invention also relates to the process for producing such compounds. The invention further relates to pharmaceutical compositions comprising such compounds optionally in combination with two or more different therapeutic agents and the use of such compounds in methods for treating diseases and conditions mediated and modulated by the GABAB receptor positive allosteric mechanism. The invention also provides a method for manufacture of medicaments useful in the treatment of such disorders.
    Type: Application
    Filed: March 12, 2018
    Publication date: February 27, 2020
    Inventors: István BORZA, Viktor ROMAN, János ÉLES, Zsuzsa HADADY, József HUSZÁR
  • Patent number: 10329296
    Abstract: The present invention relates to compounds of the general form (I). The present invention relates to new substituted diazepino-indole derivatives of the general formula (I), and to pharmaceutically acceptable salts thereof, as well as to pharmaceutical compositions comprising such compounds, to new intermediate thereof, as well as to the use of such compounds in treatment or prevention of disorders associated with melanin-concentrating hormone receptor 1 activity.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: June 25, 2019
    Assignee: Richter Gedeon NYRT.
    Inventors: Gyula Beke, János Éles, András Boros, Sándor Farkas, György Miklós Keserü
  • Publication number: 20180093989
    Abstract: The present invention relates to compounds of the general form (I). The present invention relates to new substituted diazepino-indole derivatives of the general formula (I), and to pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising such compounds, to new intermediate thereof as well as to the use of such compounds in treatment or prevention of disorders associated with melanin-concentrating hormone receptor 1 activity.
    Type: Application
    Filed: April 14, 2016
    Publication date: April 5, 2018
    Inventors: Gyula BEKE, János ÉLES, András BOROS, Sándor FARKAS, György Miklós KESERÜ
  • Patent number: 8178665
    Abstract: A process for the production of 1-(4-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone (ezetimibe) according to the following reaction scheme: (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) where the substances of the general Formulas II, IV, VI, VIII, IX, X and XI are new, Formula III is a non-isolated intermediate, R1, R2 and R3 are represented by the compounds of Formulas Va-Vd, (Va), (Vb), (Vc), (Vd) and R4 is a silyl, e.g., tert-butyl-dimethyl-silyl, tert-butyl-diphenyl-silyl group.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: May 15, 2012
    Assignee: Richter Gedeon Nyrt.
    Inventors: József Bódi, János Éles, Katalin Szöke, Krisztina Vukics, Tamás Gáti, Krisztina Temesvári, Dorottya Kiss-Bartos
  • Patent number: 8034827
    Abstract: The present invention relates to new phenanthridine derivatives of formula (I), wherein the variables are as defined in the specification, to processes for producing the same, to pharmacological compositions containing the same and to their use in therapy or prevention of painful and inflammatory processes.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: October 11, 2011
    Assignee: Richter Gegeon Nyrt.
    Inventors: Gyula Beke, Eva Bozo, Gabor Czira, Janos Eles, Sandor Farkas, Katalin Hornok, Eva Schmidt, Eva Szentirmay, Istvan Vago, Monika Vastag
  • Publication number: 20100075978
    Abstract: The present invention relates to new sulfonamide derivatives of formula (I) wherein R1-R5 and Z are as defined in the claims, and optical antipodes or racemates and/or salts and/or hydrates and/or solvates thereof, which are selective antagonists of bradykinin B1, to processes for producing these compounds, pharmacological compositions containing them and to their use in therapy or prevention of painful and inflammatory conditions.
    Type: Application
    Filed: October 27, 2007
    Publication date: March 25, 2010
    Inventors: Eva Bozo, Gyula Beke, Janos Eles, Sandor Farkas, Katalin Hornok, Gyorgy Keseru, Eva Schmidt, Eva Szentirmay, Istvan Vago, Monika Vastag
  • Publication number: 20090270411
    Abstract: The present invention relates to new phenanthridine derivatives of formula (I), wherein the variables are as defined in the specification, to processes for producing the same, to pharmacological compositions containing the same and to their use in therapy or prevention of painful and inflammatory processes.
    Type: Application
    Filed: December 19, 2006
    Publication date: October 29, 2009
    Inventors: Gyula Beke, Eva Bozo, Gabor Czira, Janos Eles, Sandor Farkas, Katalin Hornok, Eva Schmidt, Eva Szentirmay, Istvan Vago, Monika Vastag
  • Publication number: 20090216009
    Abstract: An industrially easily realizable and economical process comprising only few steps, and built on new intermediates for the production of 1-(4-3(R)-[3(S)-(4-fluorophenyl)-3-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone (ezetimibe) according to the reaction scheme described herein.
    Type: Application
    Filed: December 18, 2006
    Publication date: August 27, 2009
    Inventors: Jozsef Bodi, Janos Eles, Katalin Szoke, Krisztina Vukics, Tamas Gati, Krisztina Temesvari, Dorottya Kiss-Bartos
  • Patent number: 4279915
    Abstract: N-formylleurosine or a pharmaceutically effective salt is used in human therapy for treatment of lymphoma, leukemia or Hodgkins Disease.
    Type: Grant
    Filed: November 17, 1976
    Date of Patent: July 21, 1981
    Assignee: Richter Gedeon Vegyeszeti Gyar Rt.
    Inventors: Karola Jovanovics, Kalman Szasz, Bela Kellner, Laszlo Nemeth, Zsuzsa Relle, Emil Bittner, Eszter Deszeri, Janos Eles
  • Patent number: 4279816
    Abstract: New leurosine derivatives of the general formula (1), ##STR1## wherein R stands for hydrogen or formyl, or pharmaceutically acceptable acid addition salts thereof were prepared by oxidizing leurosine or an acid addition salt thereof, optionally formylating the thus-obtained product and then separating, and, if desired, converting any of the free bases into its acid addition salt.
    Type: Grant
    Filed: February 5, 1975
    Date of Patent: July 21, 1981
    Assignee: Richter Gedeon Vegyszeti Gyar Rt.
    Inventors: Karola Jovanovics, Kalman Szasz, Bela Kellner, Laszlo Nemeth, Zsuzsa Relle, Emil Bittner, Eszter Dezseri, Janos Eles
  • Patent number: 4279916
    Abstract: Multiple myeloma in human patients is treated by administering N-formylleurosine or its sulfate salt.
    Type: Grant
    Filed: September 20, 1977
    Date of Patent: July 21, 1981
    Assignee: Richter Gedeon Vegyeszeti Gyar Rt.
    Inventors: Karola Jovanovics, Kalman Szasz, Bela Kellner, Laszlo Nemeth, Zsuzsa Relle, Emil Bittner, Eszter Deszeri, Janos Eles
  • Patent number: 4189432
    Abstract: Leurosine derivatives of the formula (I), ##STR1## wherein R is hydrogen or formyl, or pharmaceutically acceptable acid addition salts thereof were prepared by oxidizing leurosine or an acid addition salt thereof, optionally formylating the thus-obtained product and then separating, and, if desired, converting any of the free bases into its acid addition salt. The new compounds of the invention possess strong cytostatic activity, and can be used in the human therapy with great advantage.
    Type: Grant
    Filed: December 5, 1973
    Date of Patent: February 19, 1980
    Assignee: Richter Gedeon Vegyeszeti Gyar Rt
    Inventors: Karola Jovanovics, Kalman Szasz, Bela Kellner, Laszlo Nemeth, Zsuzsa Relle, Emil Bittner, Eszter Dezseri, Janos Eles